Suchen und finden Sie den CMO / CDMO, den Sie brauchen
Discover highly skilled partners for your drug development and manufacturing project.
…
Discover highly skilled partners for your drug development and manufacturing project.
…

Seacross Pharmaceutical Co Ltd
Das Forschungs- und Entwicklungszentrum spielt eine grundlegende Rolle bei der Unterstützung der Entwicklung sowohl von Wirkstoffen als auch von fertigen Darrei
MÄRKTE: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)
BATCH-GRÖSSE: Klein, Mittel, Groß
THERAPEUTISCHE FACHGEBIETE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients
KATEGORIE/PRODUKT: FDF / DRUG PRODUCTS, CHEMICAL-SYNTHETIC
COMPLIANCE: ISP (Chile BPM), Roszdravnadzor (Russia GMP), ANMAT (Argentinien neue GMP), EMA (EU-GMP), PMDA/MHLW (Japan GMP), IFS, DIGEMID, UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), Weltgesundheitsorganisation (GMP / HACCP), MHRA (UK GMP), Französischer Dienst - öffentlich (CIR), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (China GMP), SFDA (Saudi Food & Drug Authority), BRCGS, ECOVADIS, ISO, Halal-Forschungsrat, INVIMA, Gesundheit Kanada (Kanada GMP), SQF (Sichere Lebensmittelqualität), TITCK (Turkish Health Authorities), MSPAS, MFDS/KFDA (Republik Korea GMP), COFEPRIS
KONTROLLIERTE SUBSTANZEN: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
BSL (Biologische Sicherheitsstufe): 3, 4, 1, 2
VERWENDUNG: Menschlich
DIENSTLEISTUNGEN: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
REGION: APAC
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/Tag), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1.000 µg/Tag)

Laboratorios Salvat
Vollständig integrierte CDMO-Lösungen für Blow-Fill-Seal (BFS), sterile Mehrfachdosen, unsterile Mehrfachdosen, Beutel, Kapseln und Tabletten.
BATCH-GRÖSSE: Klein, Mittel, Groß
KATEGORIE/PRODUKT: FDF / DRUG PRODUCTS, PARTICLE ENGINEERING
COMPLIANCE: EMA (EU-GMP), FDA (cGMP), ISO
REGION: Europe
VERWENDUNG: Menschlich
DIENSTLEISTUNGEN: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
MÄRKTE: FDA (USA), EMA (EU)
THERAPEUTISCHE FACHGEBIETE (ATC): (V01) Allergens, (S) Sensory organs
BSL (Biologische Sicherheitsstufe): 1
OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)
MAI network supplier
Das israelische CDMO hat sich auf die Entwicklung und GMP-Herstellung komplexer synthetischer Arzneimittelprodukte und chemiebasierter medizinischer Geräte spez
Location available after registration
MAI network supplier
Schaffen Sie erschwingliche Gesundheitslösungen, die das Leben der Patienten verbessern und vereinfachen.
Location available after registration
MAI network supplier
CDMO ist auf die Herstellung und Entwicklung von Kosmetika, Gesundheitsprodukten, Insektenschutzmitteln, Mitteln gegen Läuse/Kopfläuse und medizinischen Geräten
Location available after registration
These facilities match your main criteria but not all optional filters.

Upperton Pharma Solutions
Entwicklung und Herstellung oraler fester Dosen (OSD), nasaler, inhalativer und steriler Trockenpulver und flüssiger Arzneimittel.
BATCH-GRÖSSE: Klein, Mittel
THERAPEUTISCHE FACHGEBIETE (ATC): (R) Respiratory system, (C) Cardiovascular system, (N) Nervous system
KATEGORIE/PRODUKT: FDF / DRUG PRODUCTS, SERVICES, OLIGONUKLEOTIDE, BIOLOGIEN
KONTROLLIERTE SUBSTANZEN: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
REGION: Europe
VERWENDUNG: Menschlich
COMPLIANCE: MHRA (UK GMP)
DIENSTLEISTUNGEN: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/Tag), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1.000 µg/Tag)
MÄRKTE: FDA (USA), EMA (EU), TGA (Australia), Health Canada (Canada), MHRA (UK)
BSL (Biologische Sicherheitsstufe): 1

Lifecore Biomedical
CDMO, das klinische und kommerzielle sterile injizierbare Arzneimittelprodukte herstellt.
MÄRKTE: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)
BATCH-GRÖSSE: Klein, Mittel, Groß
KATEGORIE/PRODUKT: FDF / DRUG PRODUCTS
COMPLIANCE: EMA (EU-GMP), ANVISA (Brazil B-GMP), TGA (Australia GMP), FDA (cGMP), ECOVADIS, ISO, Gesundheit Kanada (Kanada GMP), MFDS/KFDA (Republik Korea GMP)
KONTROLLIERTE SUBSTANZEN: Lowest potential for abuse
BSL (Biologische Sicherheitsstufe): 3, 1, 2
VERWENDUNG: Menschlich, Veterinär
DIENSTLEISTUNGEN: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/Tag), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1.000 µg/Tag)
REGION: North America

AVARA
Sterile Abfüll- und Endproduktionsstätte für injizierbare Arzneimittel (Fläschchen, Ampullen, lyophilisiert).
BATCH-GRÖSSE: Klein, Mittel, Groß
KATEGORIE/PRODUKT: FDF / DRUG PRODUCTS, SERVICES
KONTROLLIERTE SUBSTANZEN: Lowest potential for abuse, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
REGION: Europe
BSL (Biologische Sicherheitsstufe): 3, 1, 2
MÄRKTE: ANVISA (Brazil), PMDA (Japan), FDA (USA), Russian Health Authorities, EMA (EU), MFDS (South Korea), MHRA (UK)
VERWENDUNG: Menschlich
DIENSTLEISTUNGEN: Analytical / QC services, Manufacturing services, Packaging, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
THERAPEUTISCHE FACHGEBIETE (ATC): (L) Antineoplastic and immunomodulating agents, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (N) Nervous system, (B) Blood and blood forming organs

MÄRKTE: DIGEMID (Peru), ANMAT (Argentina), EDE (UAE), ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)
BATCH-GRÖSSE: Klein, Mittel, Groß
THERAPEUTISCHE FACHGEBIETE (ATC): (R) Respiratory system, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system
KATEGORIE/PRODUKT: FDF / DRUG PRODUCTS
COMPLIANCE: ISP (Chile BPM), Roszdravnadzor (Russia GMP), ANMAT (Argentinien neue GMP), EMA (EU-GMP), PMDA/MHLW (Japan GMP), DIGEMID, ANVISA (Brazil B-GMP), Weltgesundheitsorganisation (GMP / HACCP), MHRA (UK GMP), Französischer Dienst - öffentlich (CIR), TGA (Australia GMP), FDA (cGMP), NMPA (China GMP), ECOVADIS, ISO, INVIMA, Gesundheit Kanada (Kanada GMP), MSPAS, MFDS/KFDA (Republik Korea GMP), COFEPRIS
REGION: Europe
VERWENDUNG: Menschlich
DIENSTLEISTUNGEN: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)

Aenova
Kompetenzzentrum Tiergesundheitsprodukte und Steriltechnik.
MÄRKTE: Turkish Health Authorities, ANVISA (Brazil), FDA (USA), Russian Health Authorities, EMA (EU), SFDA (Saudi Arabia)
BATCH-GRÖSSE: Klein, Mittel, Groß
KATEGORIE/PRODUKT: FDF / DRUG PRODUCTS
COMPLIANCE: Roszdravnadzor (Russia GMP), EMA (EU-GMP), ANVISA (Brazil B-GMP), FDA (cGMP), SFDA (Saudi Food & Drug Authority), TITCK (Turkish Health Authorities)
REGION: Europe
VERWENDUNG: Menschlich, Veterinär
DIENSTLEISTUNGEN: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1.000 µg/Tag)
BSL (Biologische Sicherheitsstufe): 1, 2

Adragos Pharma
Wir sind auf die Herstellung von Infusionsbeuteln, Kunststoffampullen und Fläschchen mit Blow-Fill-Seal (BFS)-Technologie und anderen Darreichungsformen spezial
MÄRKTE: Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), PMDA (Japan), FDA (USA), EMA (EU), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), MHRA (UK)
BATCH-GRÖSSE: Klein, Mittel, Groß
KATEGORIE/PRODUKT: FDF / DRUG PRODUCTS
COMPLIANCE: EMA (EU-GMP), PMDA/MHLW (Japan GMP), UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), Weltgesundheitsorganisation (GMP / HACCP), MHRA (UK GMP), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (China GMP), ISO, TITCK (Turkish Health Authorities), MFDS/KFDA (Republik Korea GMP)
KONTROLLIERTE SUBSTANZEN: Lowest potential for abuse, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
REGION: Europe
VERWENDUNG: Menschlich
DIENSTLEISTUNGEN: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Packaging, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1.000 µg/Tag)
THERAPEUTISCHE FACHGEBIETE (ATC): (A) Digestive tract and metabolism, (D) Dermatologicals, (V06) Nutrients

Adragos Pharma
Spezialisiert auf die Entwicklung von Arzneimitteln mit Mehrwert und wurde kürzlich mit HPAPI-Funktionen aufgerüstet.
MÄRKTE: ANMAT (Argentina), EDE (UAE), ANVISA (Brazil), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)
BATCH-GRÖSSE: Klein, Mittel, Groß
KATEGORIE/PRODUKT: FDF / DRUG PRODUCTS, SERVICES
COMPLIANCE: EMA (EU-GMP), PMDA/MHLW (Japan GMP), UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), Weltgesundheitsorganisation (GMP / HACCP), MHRA (UK GMP), FDA (cGMP), NSF, NMPA (China GMP), ISO, MFDS/KFDA (Republik Korea GMP)
KONTROLLIERTE SUBSTANZEN: Lowest potential for abuse, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
REGION: Europe
VERWENDUNG: Menschlich
DIENSTLEISTUNGEN: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/Tag), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1.000 µg/Tag)
Register to unlock the full catalog with contact details and locations.
+6 more facilities
Create free account